183 related articles for article (PubMed ID: 28158311)
1. A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma.
Wichert S; Juliusson G; Johansson Å; Sonesson E; Teige I; Wickenberg AT; Frendeus B; Korsgren M; Hansson M
PLoS One; 2017; 12(2):e0171205. PubMed ID: 28158311
[TBL] [Abstract][Full Text] [Related]
2. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
[TBL] [Abstract][Full Text] [Related]
3. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study.
Golombick T; Diamond TH; Manoharan A; Ramakrishna R
Am J Hematol; 2012 May; 87(5):455-60. PubMed ID: 22473809
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.
Hansson M; Gimsing P; Badros A; Niskanen TM; Nahi H; Offner F; Salomo M; Sonesson E; Mau-Sorensen M; Stenberg Y; Sundberg A; Teige I; Van Droogenbroeck J; Wichert S; Zangari M; Frendeus B; Korsgren M; Poelman M; Tricot G
Clin Cancer Res; 2015 Jun; 21(12):2730-6. PubMed ID: 25712687
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.
Thomas SK; Suvorov A; Noens L; Rukavitsin O; Fay J; Wu KL; Zimmerman TM; van de Velde H; Bandekar R; Puchalski TA; Qi M; Uhlar C; Samoylova OS
Cancer Chemother Pharmacol; 2014 Jan; 73(1):35-42. PubMed ID: 24149943
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes in biclonal gammopathies.
Mullikin TC; Rajkumar SV; Dispenzieri A; Buadi FK; Lacy MQ; Lin Y; Dingli D; Go RS; Hayman SR; Zeldenrust SR; Russell SJ; Lust JA; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Am J Hematol; 2016 May; 91(5):473-5. PubMed ID: 26840395
[TBL] [Abstract][Full Text] [Related]
11. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
Maciocia N; Wechalekar A; Yong K
Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
[TBL] [Abstract][Full Text] [Related]
13. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E; Migkou M; Christoulas D; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanellias N; Iakovaki M; Panagiotidis I; Ziogas DC; Fotiou D; Kastritis E; Dimopoulos MA
Blood Cancer J; 2016 May; 6(5):e428. PubMed ID: 27232930
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
Hillengass J; Moehler T; Hundemer M
Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
[TBL] [Abstract][Full Text] [Related]
16. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis.
Kavanaugh AF; Davis LS; Jain RI; Nichols LA; Norris SH; Lipsky PE
J Rheumatol; 1996 Aug; 23(8):1338-44. PubMed ID: 8856611
[TBL] [Abstract][Full Text] [Related]
19. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Willrich MAV; Murray DL; Kyle RA
Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
[TBL] [Abstract][Full Text] [Related]
20. [Smoldering multiple myeloma].
Fouquet G; Guidez S; Herbaux C; Demarquette H; Leleu X
Rev Med Interne; 2014 Apr; 35(4):243-9. PubMed ID: 24050785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]